New live attenuated TB vaccine is safe and shows a distinct, dose dependent immune response in a Phase 1b trial in newborns

Biofabri, the University of Zaragoza, the South African Tuberculosis Vaccine Initiative (SATVI) and TB Vaccine Initiative (TBVI) announced the results of a Phase 1b trial of the new live attenuated TB vaccine ‘MTBVAC’ at the 5th Global Forum on TB vaccines, held on 20-23 February 2018 in New Delhi, India.